2024
Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States
Neparidze N, W. Lau K, Wang X, Huntington S, Jamy O, S. Calip G, Shah H, M. Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic among Patients with Hematologic Malignancies in the United States. Medical Research Archives 2024, 12 DOI: 10.18103/mra.v12i2.5164.Peer-Reviewed Original ResearchAcute myelogenous leukemiaMantle cell lymphomaChronic lymphocytic leukemiaDiffuse large B-cell lymphomaFollicular lymphomaMultiple myelomaWhite patientsBlack patientsCell lymphomaHematologic malignanciesLymphocytic leukemiaTreatment categoriesElectronic health record (EHR)-derived de-identified databaseDiagnosis of acute myelogenous leukemiaLarge B-cell lymphomaTelemedicine uptakeActive patientsLines of therapyB-cell lymphomaMonthly visit ratesMyeloma patientsVisit ratesAnalyzed patientsMyelogenous leukemiaLymphoma
2023
Impact of the COVID-19 pandemic on treatment approaches of multiple myeloma
Theprungsirikul P, Neparidze N. Impact of the COVID-19 pandemic on treatment approaches of multiple myeloma. Medical Research Archives 2023, 11 DOI: 10.18103/mra.v11i6.3912.Peer-Reviewed Original ResearchMultiple myelomaCOVID-19 infectionHematologic malignanciesTreatment approachesCOVID-19 pandemicAutologous stem cell transplantCoronavirus disease-19 (COVID-19) patientsImmune therapy approachesCellular immune dysfunctionRefractory multiple myelomaManagement of patientsStem cell transplantClinical practice guidelinesCommon hematologic malignancySevere clinical outcomesEarly pandemic periodCOVID-19Stable diseaseMajor comorbiditiesSteroid regimensCytotoxic chemotherapySupportive careImmune dysfunctionPrompt diagnosisTreatment initiation
2021
Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States
Goyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States. Blood 2021, 138: 1930. PMCID: PMC8701834, DOI: 10.1182/blood-2021-153625.Peer-Reviewed Original ResearchCurrent equity holderEarly pandemic monthsLines of therapyHematologic malignanciesVisit ratesTreatment typePandemic monthsAdvisory CommitteeCAR T-cell therapyPerson medical careDiagnosis of AMLDe-identified databaseCOVID-19 pandemicSignificant reductionPandemic periodCurrent employmentElectronic health recordsFlatiron HealthOral therapyActive treatmentHematopoietic transplantsInitial diagnosisCSL BehringOutpatient infusionsActive patientsRacial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States
Neparidze N, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States. Blood 2021, 138: 1973. PMCID: PMC8701527, DOI: 10.1182/blood-2021-153787.Peer-Reviewed Original ResearchCurrent equity holderWhite patientsBlack patientsInpatient treatmentVisit ratesTelemedicine uptakeTreatment categoriesPerson visitsHematologic malignanciesAdvisory CommitteeTreatment typeSignificant reductionRacial disparitiesLines of therapyDiagnosis of AMLDe-identified databaseEarly pandemic monthsPotential racial disparitiesCurrent employmentElectronic health recordsFlatiron HealthHospital admissionActive treatmentInitial diagnosisCSL Behring
2011
Understanding the Role of Natural Killer T Cells in Hematologic Malignancies: Progress and Challenges
Neparidze N, Dhodapkar M. Understanding the Role of Natural Killer T Cells in Hematologic Malignancies: Progress and Challenges. Cancer Drug Discovery And Development 2011, 153-167. DOI: 10.1007/978-1-4614-0613-6_9.Peer-Reviewed Original ResearchNatural killer T cellsKiller T cellsNKT cellsHematologic malignanciesT cellsImportant effector cellsPreliminary clinical studyAnti-tumor effectsNKT functionDendritic cellsTumor immunityEffector cellsHematologic tumorsClinical studiesMalignancyQualitative defectsPatientsCD1dType IAttractive targetCellsVivoClinicNKTTumors